Table of Contents

1 Study Coverage

• 1.1 Oncolytic Virus Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Oncolytic Virus Market Size Growth Rate by Product
  • 1.4.2 HSV-based Oncolytic Viruses
  • 1.4.3 Adenoviruses-based Oncolytic Viruses
  • 1.4.4 Vaccinia Virus-based Oncolytic Viruses
  • 1.4.5 Vesicular Stomatitis Virus-based Oncolytic Viruses
  • 1.4.6 Newcastle Disease Virus-based Oncolytic Viruses
• 1.5 Market by End User
  • 1.5.1 Global Oncolytic Virus Market Size Growth Rate by End User
  • 1.5.2 Pharmaceutical
  • 1.5.3 Health Care
  • 1.5.4 Commerical
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Oncolytic Virus Market Size
  • 2.1.1 Global Oncolytic Virus Revenue 2014-2025
  • 2.1.2 Global Oncolytic Virus Sales 2014-2025
• 2.2 Oncolytic Virus Growth Rate by Regions
  • 2.2.1 Global Oncolytic Virus Sales by Regions
  • 2.2.2 Global Oncolytic Virus Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Oncolytic Virus Sales by Manufacturers
  • 3.1.1 Oncolytic Virus Sales by Manufacturers
  • 3.1.2 Oncolytic Virus Sales Market Share by Manufacturers
  • 3.1.3 Global Oncolytic Virus Market Concentration Ratio (CR5 and HHI)
• 3.2 Oncolytic Virus Revenue by Manufacturers
  • 3.2.1 Oncolytic Virus Revenue by Manufacturers (2014-2019)
  • 3.2.2 Oncolytic Virus Revenue Share by Manufacturers (2014-2019)
• 3.3 Oncolytic Virus Price by Manufacturers
• 3.4 Oncolytic Virus Manufacturing Base Distribution, Product Types
  • 3.4.1 Oncolytic Virus Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Oncolytic Virus Product Type
  • 3.4.3 Date of International Manufacturers Enter into Oncolytic Virus Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Oncolytic Virus Sales by Product
• 4.2 Global Oncolytic Virus Revenue by Product
• 4.3 Oncolytic Virus Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Oncolytic Virus Breakdown Data by End User

6 North America

• 6.1 North America Oncolytic Virus by Countries
  • 6.1.1 North America Oncolytic Virus Sales by Countries
  • 6.1.2 North America Oncolytic Virus Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Oncolytic Virus by Product
• 6.3 North America Oncolytic Virus by End User

7 Europe

• 7.1 Europe Oncolytic Virus by Countries
  • 7.1.1 Europe Oncolytic Virus Sales by Countries
  • 7.1.2 Europe Oncolytic Virus Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Oncolytic Virus by Product
• 7.3 Europe Oncolytic Virus by End User

8 Asia Pacific

• 8.1 Asia Pacific Oncolytic Virus by Countries
  • 8.1.1 Asia Pacific Oncolytic Virus Sales by Countries
  • 8.1.2 Asia Pacific Oncolytic Virus Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Oncolytic Virus by Product
• 8.3 Asia Pacific Oncolytic Virus by End User

9 Central & South America

• 9.1 Central & South America Oncolytic Virus by Countries
  • 9.1.1 Central & South America Oncolytic Virus Sales by Countries
  • 9.1.2 Central & South America Oncolytic Virus Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Oncolytic Virus by Product
• 9.3 Central & South America Oncolytic Virus by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Oncolytic Virus by Countries
  • 10.1.1 Middle East and Africa Oncolytic Virus Sales by Countries
  • 10.1.2 Middle East and Africa Oncolytic Virus Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Oncolytic Virus by Product
• 10.3 Middle East and Africa Oncolytic Virus by End User

11 Company Profiles

• 11.1 Merck
  • 11.1.1 Merck Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Merck Oncolytic Virus Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Merck Oncolytic Virus Products Offered
  • 11.1.5 Merck Recent Development
• 11.2 Otsuka Pharmaceutical Co
  • 11.2.1 Otsuka Pharmaceutical Co Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Otsuka Pharmaceutical Co Oncolytic Virus Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Otsuka Pharmaceutical Co Oncolytic Virus Products Offered
  • 11.2.5 Otsuka Pharmaceutical Co Recent Development
• 11.3 Pfizer
  • 11.3.1 Pfizer Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Pfizer Oncolytic Virus Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Pfizer Oncolytic Virus Products Offered
  • 11.3.5 Pfizer Recent Development
• 11.4 Roche
  • 11.4.1 Roche Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Roche Oncolytic Virus Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Roche Oncolytic Virus Products Offered
  • 11.4.5 Roche Recent Development
• 11.5 Cold Genesys
  • 11.5.1 Cold Genesys Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Cold Genesys Oncolytic Virus Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Cold Genesys Oncolytic Virus Products Offered
  • 11.5.5 Cold Genesys Recent Development
• 11.6 Genelux
  • 11.6.1 Genelux Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Genelux Oncolytic Virus Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Genelux Oncolytic Virus Products Offered
  • 11.6.5 Genelux Recent Development
• 11.7 Latima
  • 11.7.1 Latima Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Latima Oncolytic Virus Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Latima Oncolytic Virus Products Offered
  • 11.7.5 Latima Recent Development
• 11.8 Neotropix
  • 11.8.1 Neotropix Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Neotropix Oncolytic Virus Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Neotropix Oncolytic Virus Products Offered
  • 11.8.5 Neotropix Recent Development
• 11.9 Shanghai Sunway Biotech
  • 11.9.1 Shanghai Sunway Biotech Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Shanghai Sunway Biotech Oncolytic Virus Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Shanghai Sunway Biotech Oncolytic Virus Products Offered
  • 11.9.5 Shanghai Sunway Biotech Recent Development
• 11.10 SillaJen
  • 11.10.1 SillaJen Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 SillaJen Oncolytic Virus Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 SillaJen Oncolytic Virus Products Offered
  • 11.10.5 SillaJen Recent Development
• 11.11 Takara Bio
• 11.12 Theravir

12 Future Forecast

• 12.1 Oncolytic Virus Market Forecast by Regions
  • 12.1.1 Global Oncolytic Virus Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Oncolytic Virus Revenue Forecast by Regions 2019-2025
• 12.2 Oncolytic Virus Market Forecast by Product
  • 12.2.1 Global Oncolytic Virus Sales Forecast by Product 2019-2025
  • 12.2.2 Global Oncolytic Virus Revenue Forecast by Product 2019-2025
• 12.3 Oncolytic Virus Market Forecast by End User
• 12.4 North America Oncolytic Virus Forecast
• 12.5 Europe Oncolytic Virus Forecast
• 12.6 Asia Pacific Oncolytic Virus Forecast
• 12.7 Central & South America Oncolytic Virus Forecast
• 12.8 Middle East and Africa Oncolytic Virus Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Oncolytic Virus Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

The global Oncolytic Virus market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Oncolytic Virus market based on company, product type, end user and key regions.

This report studies the global market size of Oncolytic Virus in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Oncolytic Virus in these regions.
This research report categorizes the global Oncolytic Virus market by top players/brands, region, type and end user. This report also studies the global Oncolytic Virus market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Merck
Otsuka Pharmaceutical Co
Pfizer
Roche
Cold Genesys
Genelux
Latima
Neotropix
Shanghai Sunway Biotech
SillaJen
Takara Bio
Theravir

Market size by Product
HSV-based Oncolytic Viruses
Adenoviruses-based Oncolytic Viruses
Vaccinia Virus-based Oncolytic Viruses
Vesicular Stomatitis Virus-based Oncolytic Viruses
Newcastle Disease Virus-based Oncolytic Viruses
Market size by End User
Pharmaceutical
Health Care
Commerical

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Oncolytic Virus market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Oncolytic Virus market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Oncolytic Virus companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Oncolytic Virus submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Oncolytic Virus are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Oncolytic Virus market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.